Mr. Eugene Cherny reports

CHEELCARE REPORTS SECOND CONSECUTIVE MONTH OF RECORD COMPANION BOOKINGS WITH APRIL BOOKINGS UP 147% YEAR-OVER-YEAR AND 38.5% SEQUENTIALLY

Cheelcare Inc. has provided an update on preliminary record monthly bookings for April, 2026, for its Companion power assist product line, representing the second consecutive month for record bookings for growth.

Bookings for April, 2026, increased 147 per cent year over year and 38.5 per cent compared with March, 2026, representing the second consecutive month of record Companion bookings. Management also reported a significant increase in request for quotations (RFQs) across North America, which the company views as a leading indicator of future demand and sales activity.

The accelerating momentum follows Cheelcare's previously announced achievement of the U.S. Medicare and Medicaid reimbursement eligibility for the Companion platform in January, 2026, which expanded insurance-financed access to the product and reduced reliance on private-pay purchasing. Since that milestone, the company has seen increasing engagement from dealers, clinicians, therapists and funding agencies across multiple jurisdictions.

The company also reported continued acceleration in RFQs, with April, 2026, RFQ activity increasing approximately 64 per cent compared with March, 2026, and more than doubling relative to January, 2026. Management views RFQs as an important leading indicator of future bookings and revenue activity.

"We believe we are now beginning to see the early impact of the reimbursement and clinical adoption groundwork the company has spent years building," said Eugene Cherny, chief executive officer of Cheelcare. "The combination of back-to-back record booking months, increasing RFQ activity, and growing reimbursement-supported access is encouraging and may represent the beginning of a new growth curve for the Companion platform."

Bookings represent customer purchase orders received during the period and may not align directly with revenue recognized under IFRS (international financial reporting standards) accounting standards due to production timing, shipment schedules and other revenue recognition factors. Management expects a substantial portion of bookings to convert into future revenue.

Cheelcare also continued to expand its industry presence during the quarter through participation in several major mobility and rehabilitation conferences and events, including the Abilities Expo Los Angeles, Abilities Expo New York, and the Canadian Seating and Mobility Conference (CSMC) East. The company believes these events continue to strengthen relationships with clinicians, therapists, dealers and end-users while increasing awareness of the Companion and Curio product platforms.

At CSMC East, occupational therapist and Cheelcare board member Sheila Buck, BSc (occupational therapy), RegOT (Ontario), of Therapy NOW presented on the real-world application of Cheelcare's mobility technologies and their impact on independence and mobility outcomes for users.

"With expanding reimbursement access, increasing commercial activity and growing market awareness, we believe Cheelcare is well positioned entering fiscal 2026," added Mr. Cherny.

About Cheelcare Inc.

Cheelcare designs and manufactures innovative mobility solutions that empower independence for people with disabilities. From the Companion power assist devices to the groundbreaking Curio robotic complex-rehab power wheelchair, Cheelcare combines engineering excellence with human-centred design to improve quality of life.

We seek Safe Harbor.